Multi-faceted arginine: Mechanism of the effects of arginine on protein

Current Protein and Peptide Science

Volumn 15, Issue 6, 2014, Pages 608-620

  Arakawa, Tsutomu ^a   Kita, Yoshiko ^b  

^a ALLIANCE PROTEIN LABORATORIES   (United States)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Aggregation suppression; Arginine; Biotechnology; Hydration; Preferential interaction; Refolding

Indexed keywords

AMINO ACID; ARGININE; BETA 2 MICROGLOBULIN; COSOLVENT; GREEN FLUORESCENT PROTEIN; MACROGOL; MEMBRANE PROTEIN; ORGANIC SOLVENT; POLYMER; POLYOL; PROTEIN; SOLVENT; SUGAR; UNCLASSIFIED DRUG; VELAFERMIN; EXCIPIENT; PROTEIN AGGREGATE;

AFFINITY CHROMATOGRAPHY; BIOLOGICAL AFFINITY CHROMATOGRAPHY; CAVITY THEORY; CRYSTAL STRUCTURE; CRYSTALLIZATION; GEL PERMEATION CHROMATOGRAPHY; HYDROPHOBIC INTERACTION CHROMATOGRAPHY; ION EXCHANGE CHROMATOGRAPHY; PHYSICAL CHEMISTRY; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN DENATURATION; PROTEIN INTERACTION; PROTEIN REFOLDING; PROTEIN STABILITY; PROTEIN STRUCTURE; REVIEW; SOLUBILIZATION; SOLVENT EFFECT; SURFACE TENSION; THEORY; THERMODYNAMICS; VIRUS INACTIVATION; ANIMAL; CHEMISTRY; DRUG EFFECTS; HUMAN; MEDICINAL CHEMISTRY; METABOLISM; PROCEDURES; SOLUBILITY; ARTICLE; DRUG FORMULATION; EQUILIBRIUM CONSTANT; MOLECULAR DYNAMICS; PROTEIN ASSEMBLY; PROTEIN BINDING; PROTEIN EXPRESSION;

ANIMALS; ARGININE; CHEMISTRY, PHARMACEUTICAL; EXCIPIENTS; HUMANS; PROTEIN AGGREGATES; PROTEIN DENATURATION; PROTEIN REFOLDING; PROTEINS; SOLUBILITY;

EID: 84906907540     PISSN: 13892037     EISSN: 18755550     Source Type: Journal    
DOI: 10.2174/138920371506140818113015     Document Type: Review

References (205)

1. Dioguardi, F.S. To give or not to give. J. Nutrigenet. Nutrigenomics., 2011, 4, 90-98.
2. Tsumoto, K.; Ejima, D.; Kumagai, I.; Arakawa, T. Practical consideration in refolding proteins from inclusion bodies. Protein Expr. Purif., 2003 28, 1-8.
3. Arakawa, T.; Tsumoto, K; Kita, Y.; Chang, B.; Ejima, D. Biotechnology applications of amino acids in protein purification and formulations. Amino Acids, 2007 33, 587-605.
4. Lange, C.; Rudolph, R. Suppression of protein aggregation by Larginine. Curr. Pharm. Biotechnol., 2009 10, 408-414.
5. Arakawa, T. Role of arginine in development of biopharmaceuticals. Yakugaku Zasshi, 2010 130, 793-800.
6. Tsumoto, K.; Ejima, D.; Kita, Y.; Arakawa, T. Review: why is arginine effective in suppressing aggregation? Protein Pept. Lett., 2005, 12, 613-619.
7. Arakawa, T., Kita, Y.; Ejima, D.; Tsumoto, K.; Fukada, H. Aggregation suppression of proteins by arginine during thermal unfolding. Protein Pept. Lett., 2006, 13,921-927.
8. Rudolph, R.; Lilie, H. In vitro folding of inclusion bodies. FASEB. J., 1996 10, 49-56.
9. Clark, E.D.B. Refolding of recombinant proteins. Curr. Opin. Biotechnol., 1999 9, 157-163.
10. Clark, E.D.B.; Schwarz, E.; Rudolph, R. Inhibition of aggregation side reactions during in vitro protein folding. Methods Enzymol, 1999 309, 217-236.
11. Rudolph. R.; Fisher, S. Process for obtaining renatured proteins. US patent 4, 933, 434, June 12, 1990.
12. Umetsu, M.; Tsumoto, K.; Hara, M.; Ashish, K.; Goda, S.; Adshiri, T.; Kumagai, I. How additives influence the refolding of immunoglobulin-folded proteins in a stepwise dialysis system. Spectroscopic evidence for highly efficient refolding of a single-chain Fv fragment. J. Biol. Chem., 2003 278, 8979-8987.
13. Reddy, K.R.C.; Lilie, H.; Rudolph, R.; Lange C. L-Arginine increases the solubility of unfolded species of hen egg white lysozyme. Protein Sci., 2005 14, 929-935.
14. Armstrong, N.; de Lencastre, A.; Gouaux, E. A new protein folding screen: application to the ligand binding domains of a glutamate and kainite receptor and to lysozyme and carbonic anhydrase. Protein Sci., 1999 8, 1475-1483.
15. Oneda, H.; Inouye, K. Refolding and recovery of recombinant human matrix metalloproteinase (matrilysin) from inclusion bodies expressed by Escherichia voli. J. Biochem., 1999 126, 905-911.
16. Arora, D.; Khanna, N. Method for increasing the yield of properly folded recombinant human gamma interferon from inclusion bodies. J. Biotechnol., 1996 52, 127-133.
17. Suenaga, M.; Ohmae, H.; Tsuji, S.; Itoh, T.; Nishimura, O. Renaturation of recombinant human neurotrophin-3 from inclusion bodies using a suppressor agent of aggregation. Biotechnol. Appl. Biochem., 1998 28, 119-124.
18. Rattenholl, A.; Ruoppolo, M.; Flagiello, A.; Monti, M.; Vinci, F.; Marino, G.; Lilie, H.; Schwarz, E.; Rudolph, R. Pro-sequence assisted folding and disulfide bond formation of human nerve growth factor. J. Mol. Biol., 2001 305, 523-533.
19. Asano, R.; Kudo, T.; Makabe, K.; Tsumoto, K.; Kumagai, I. Antitumor activity of interleukin-21 prepared by novel refolding procedure from inclusion bodies expressed in Escherichia coli. FEBS Lett., 2002 528, 70-76.
20. Bajorunaite, E.; Sereikaite, J.; Bumelis, V. L-arginine suppresses aggregation of recombinant growth hormones in refolding process from E. coli inclusion bodies. Protein J., 2007, 26, 547-555.
21. Takahashi, S.; Ogasawara, H.; Watanabe, T.; Kumagai, M.; Inoue, H.; Hori, K. Refolding and activation of human prorenin expressed in Escherichia coli: application of recombinant human renin for inhibitor screening. Biosci. Biotechnol. Biochem., 2006 70, 2913-2918.
22. Lechtken, A.; Zundorf, I.; Dingermann, T.; Firla, B.; Steinhiber, D. Overexpression, refolding, and purification of polyhistidine-tagged human retinoic acid related orphan receptor RORalpha4. Protein Expr. Purif., 2006 49, 114-120.
23. Hsih, M.H.; Kuo, J.C.; Tsai, H.J. Optimization of the solubilization and renaturation of fish growth hormone produced by Escherichia coli. Appl. Microbiol. Biotechnol., 1997 48, 66-72.
24. Wang, X.T.; Engel, P.C. An optimized system for refolding of human glucose 6-phosphate dehydrogenase. BMC Biotechnol., 2009 9, 19-29.
25. Rudolph, R.; Opitz, U.; Hesse, F.; Riebland, R.; Fischer, S. In: Biotechnology International; North, Ed.; Century Press: London, 1992; pp. 321-325.
26. Rinas, U.; Risse, B.; Jaenicke, R.; Abel, K.J.; Zettlmeissl, G. Denaturation-renaturation of the fibrin-stabilizing factor XIII a-chain isolated from human placenta: properties of the native and reconstituted protein. J. Biol. Chem., 1990 371, 49-56.
27. Ahn, J.H.; Lee, Y.P.; Rhee, J.S. Investigation of refolding condition for Pseudomonas fluorescence lipase by response methodology. J. Biotech., 1997 54, 151-160.
28. Huston, J.S.; Tai, M.S.; McCartney, J.; Keck, P.; Oppermann, H. Antigen recognition and targeted delivery by the single-chain Fv. Cell Biphys., 1993 22, 189-124.
29. Ross, C.N.; Turner, N.; Sevage, P.; Cashman, S.J.; Spooner, R.A.; Pusey, C.D. A single-chain Fv reactive with the Goodpasture antigen. Lab. Invest., 1996, 74, 1051-1059.
30. De Jonge, J.; Brissinck, J.; Heirman, C.; Demanet, C.; Leo, O.; Moser, M. Thielemans, K. Production and characterization of bispecific single-chain antibody. Mol. Immunol., 1995 32, 1405-1412.
31. Makayashiki, N.; Yoshikawa, K.; Nakamura, K.; Hanai, N.; Okamoto, K.; Okamoto, S.; Mizuno, M.; Wakabayashi, T.; Saga, S.; Yoshida, J.; Takahashi, T. Production of a single-chain variable fragment antibody recognizing type III mutant epidermal growth factor receptor. Jpn. J. Cancer Res., 2000 91, 1035-1043.
32. D'Alatri, L.; Di Massimo, A.M.; Anastasi, A.M.; Pacilli, A.; Novelli, S.; Saccinto, M.P.; De Santis, R.; Mele, A.; Parente, D. Production and characterization of a recombinant single-chain anti ErbB2-clavin immunotoxin. Anticancer Res., 1998 18, 3369-3373.
33. Buchner, J.; Rudolph, R. Renaturation, purification and characterization of recombinant Fab-fragments produced in Escherichia coli. Bio/Technology, 1991 9, 157-162.
34. Brinkmann, U.; Buchner, J.; Pastan I. Independent domain folding of Pseudomonas exotoxin and single-chain immunotoxins: influence of interdomain connections. Proc. Natl. Acad. Sci. USA., 1992 89, 3075-3079.
35. Buchner, J.; Pastan, I.; Brinkmann, U. A method for increasing the yield of properly folded recombinant fusion proteins: single-chain immunotoxins from renaturation of bacterial inclusion bodies. Anal. Biochem., 1992 205, 263-270.
36. Tsumoto, K.; Shinoki, K.; Kondo, H.; Uchikawa, M.; Juji, T.; Kumagai, I. Highly efficient recovery of functional single-chain Fv fragments from inclusion bodies overexpressed in Escherichia coli by controlled introduction of oxidizing reagent-application to a human single-chain Fv fragments. J. Immunol. Methods, 1998 219, 119-129.
37. Fujii, T.; Ohkuri, T.; Onodera, R.; Ueda, T. Stable supply of large amounts of human Fab from the inclusion bodies in E. coli. J. Biochem., 2007, 141, 699-670.
38. Kudou, M.; Yumioka, R.; Ejima, D.; Arakawa, T.; Tsumoto, K. A novel protein refolding system using lauroyl-l-glutamate as a solubilizing detergent and arginine as folding assisting agent. Protein Expr. Purif., 2011 75, 46-54.
39. Kudou, M.; Ejima, D.; Sato, H.; Yumioka, R.; Arakawa, T.; Tsumoto, K. Refolding single-chain antibody (scFv) using lauroyl-Lglutamate as a solubilization detergent and arginine as refolding additive. Protein Expr. Purif., 2011 77, 68-74.
40. Hart, R.A.; Rinas, U.; Bailey, J.E. Protein composition of Vitreoscilla hemoglobin inclusion bodies produced in Escherichia coli. J. Biol. Chem., 1990 265, 12728-12733.
41. Jung, G.; Denefle, P.; Becquart, J.; Mayaux, J.F. High-cell density fermentation studies of recombinant Escherichia coli strains expressing interleukin-1 beta. Ann. Inst. Pasteur. Microbiol., 1988 139, 129-146.
42. Tsumoto, K.; Umetsu, M.; Kumagai, I.; Ejima, D.; Arakawa, T. Solubilization of active green fluorescent protein from inclusion particles by guanidine and arginine. Biochem. Biophys. Res. Commun., 2003 312, 1383-1386.
43. Umetsu, M.; Tsumoto, K.; Nitta, S.; Adschiri, T.; Ejima, D.; Arakawa, T.; Kumagai, I. Nondenaturing solubilization of beta2 microglobulin from inclusion bodies by L-arginine. Biochem. Biophys. Res. Commun., 2005 328, 189-197.
44. Arakawa, T.; Tsumoto, K. The effects of arginine on refolding aggregated proteins: not facilitate refolding, but suppress aggregation. Biochem. Biophys. Res. Commun., 2003 304, 148-152.
45. Jeffers, M.; McDonald, W.F.; Chillakuru, R.A.; Yang, M.; Nakase, H.; Deegler, L.L.; Sylander, E.D.; Rittman, B.; Bendele, A.; Sartor, B.; Lichenstein, H.S. A novel human fibroblast growth factor treats experimental intestinal inflammation. Gastroenterology, 2002 1123, 1151-1162.
46. Maity, H.; Karkaria, C.; Davagino, J. Mapping of solution components, pH changes, protein stability and the elimination of protein precipitation during freeze-thawing of fibroblast growth factor 20. Int. J. Pharm., 2009 378, 122-135.
47. Maity, H.; Karkaria, C.; Davagnino, J. Effects of pH and arginine on the solubility and stability of a therapeutic protein (Fibroblast Growth Factor 20): relationship between solubility and stability. Curr. Pharm. Biotechnol., 2009 10, 609-625.
48. Arakawa. J.; Uegaki, M., Ishimizu, T. Effects of L-arginine on solubilization and purification of plant membrane proteins. Protein. Expr. Purif., 2011 80, 91-96.
49. Arakawa, T.; Kita, Y.; Koyama, A.H. Solubility enhancement of gluten and coumarin by arginine. Int. J. Pharm., 2008 355, 220-223.
50. Hirano, A.; Arakawa, T.; Shiraki, K. Arginine increases the solubility of coumarin: comparison with salting-in and salting-out additives. J. Biochem., 2008 144, 363-369.
51. Arakawa, T.; Uozaki, M.; Koyama, A.H. Modulation of small molecule solubility and protein binding by arginine. Mol. Med. Report, 2010 3, 833-836.
52. Hirano, A.; Kameda, T.; Arakawa, T.; Shiraki, K. Arginine-assisted solubilization system for drug substances: solubility experiment and simulation. J. Phys. Chem. B., 2010 114, 13455-13462.
53. Dawson, C.R.; Beck, R.; Wilhelmus, K.R.; Cohen, E.J. Herpetic eye disease study. You can help. Arch. Ophthalmol., 1996 114, 89-90.
54. Shiraki, K.; Kurokawa, M. Antiherpetic chemotherapy. Nippon Rinsho, 2000 58, 938-943.
55. Shiraki, K. Anti herpetic chemotherapeutic drugs. Nippon Rinsho, 2003 61, 792-797.
56. Ghosh, R.; Sharma, S.; Chattopadhyay, K. Effect of arginine on protein aggregation studied by fluorescence correlation spectroscopy and other biophysical techniques. Biochemistry, 2009 48, 1135-1143.
57. Arakawa, T.; Dix, D.B.; Chang, B.S. The effects of protein stabilizers on aggregation induced by multiple-stresses. Yakugaku Zasshi, 2003 123, 957-961.
58. Arakawa, T.; Ejima, D.; Tsumoto, K.; Obeyama, N.; Tanaka, Y.; Kita, Y.; Timasheff, S.N. Suppression of protein interactions by ar ginine: a proposed mechanism of the arginine effects. Biophys. Chem., 2007 127, 1-8.
59. Tsumoto, K.; Umetsu, M.; Kumagai, I.; Ejima, D.; Philo, J.S.; Arakawa, T. Role of arginine in protein refolding, solubilization, and purification. Biotechnol. Prog., 2004 20, 1301-1308.
60. Shiraki, K.; Kudou, M.; Fujiwara, S.; Imanaka, T.; Takagi, M. Biophysical effect of amino acids on the prevention of protein aggregation. J. Biochem., 2002 132, 591-595.
61. Kudou, M.; Shiraki, K.; Fujiwara, S.; Imanaka, T.; Takagi, M. Prevention of thermal inactivation and aggregation of lysozyme by polyamines. Eur. J. Biochem., 2003 270, 4547-4554.
62. Shiraki, K.; Kudou, M.; Nishikori, S.; Kitagawa, H.; Imanaka, T.; Takagi, M. Arginineethylester prevents thermal inactivation and aggregation of lysozyme. Eur. J. Biochem., 2004 271, 3242-3247.
63. Reddy, K.R.; Lilie, H.; Rudolph, R. C.; Lange, C. L-Arginine increases the solubility of unfolded species of hen egg white lysozyme. Protein Sci., 2005 14, 929-935.
64. Tischer, A.; Lilie, H.; Rudolph, R.; Lange, C. L-arginine hydrochloride increases the solubility of folded and unfolded recombinant plasminogen activator rPA. Protein Sci., 2010 19, 1783-1795.
65. Srinivas, V.; Raman, B.; Rao, K.S.; Ramakrishna, T.; Rao, Ch. M. Structural perturbation and enhancement of the chaperone-like activity of alpha-crystallin by arginine hydrochloride. Protein Sci., 2003 12, 1262-1270.
66. Alvarez, E.; Fey, E.G.; Valax, Z.; Yim, Z.; Peterson, J.D.; Mesri, M.; Jeffers, M.; Dindinger, M.; Twomlow, N.; Ghatpande, A.; LaRochelle, W.J.; Sonis, S.T.; Lichenstein, H.S. Preclinical characterization f CG53135 (FGF-20) in radiation and concomitant chemotherapy/ radiation-induced oral mucositis. Clin. Cancer Res., 2003 9, 3454-3461.
67. van der Walt, J.M.; Noureddine, M.A.; Kittappa, R.; Hauser, M.A.; Scott, W.K.; McKay, R.; Zhang, F.; Stajich, J.M.; Fujiwara, K.; Scott, B.L.; Pericak-Vance, M.A.; Vance, J.M.; Martin, E.R. Fibroblast growth factor 20 polymorphisms and haplotypes strongly influence risk of Parkinson disease. Am. J. Hum. Genet., 2004 74, 1121-1127.
68. Yadav, S.; Shire, S.J.; Kalonia, D.S. Factors affecting the viscosity in high concentration solutions of different monoclonal antibodies. J. Pharm. Sci., 2010 99, 4812-4829.
69. Mattern, M.; Winter, G.; Kohnert, U.; Lee, G. Formulation of proteins in vacuum-dried glasses. II. Process and storage stability in sugar-free amino acid systems. Pharm. Dev. Technol., 1999 4, 199-208.
70. Ohtake, S.; Schebor, C.; Palecek, S.P.; de Pablo, J.J. Effect of pH, counter ion, and phosphate concentration on the glass transition temperature of freeze-dried sugar-phosphate mixtures. Pharm. Res., 2004 21, 1615-1621.
71. Izutsu, K.; Yoshioka, S.; Takeda, Y. The effects of additives on the stability of freeze-dried _-galactosidase stored at elevated temperature. Int. J. Pharm., 1991 71, 137-146.
72. Tian, F.; Sane, S.; Rytting, J.H. Calorimetric investigation of protein/ amino acid interactions in the solid state. Int. J. Pharm., 2006 310, 175-186.
73. Wang, W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int. J. Pharm., 1999 185, 129-188.
74. Jones, A.J.S. Analysis of polypeptides and proteins. Adv. Drug Deliv. Rev., 1993 10, 29-90.
75. Chang, B.S.; Hershenson, S. Practical approaches to protein formulation development. Pharm. Biotechnol., 2002 13, 1-25.
76. Hartmen, W.K.; Septharishi, N.; Yang, X.Y.; Mitra, G.; Soman, G. Characterization and analysis of thermal denaturation of antibodies by size exclusion high-performace liquid chromatography with quadruple detection. Anal. Biochem., 2005 325, 227-239.
77. Regnier F. High-performance liquid chromatography of biopolymers. Science, 1983 222, 245-252.
78. Stulik, K.; Pacakova, V.; Ticha, M. Some potentialities and drawbacks of contemporary size-exclusion chromatography. J. Biochem. Biophys. Methods, 2003 56, 1-13.
79. Pacáková, V.; Stulik, K.; Hau, P.T.; Jelinek, I.; Vins, I.; Sýkora D., Comparison of high-performance liquid chromatography and capillary electrophoresis for the determination of some bee venom components. J. Chromatogr. A, 1995 700, 187-193.
80. Pfannkoch, E.; Lu, K.; Regnier, F.; Barth, H. Characterization of some commercial hihg-performance size-exclusion chromatography columns for water0soluble polymers. J. Chromatogr. Sci., 1980 18, 430-441.
81. Watson, E.; Kenney, W.C. High-performance size-exclusion chromatography of recombinant derived proteins and aggregated species. J. Chromatogr., 1988 436, 289-298.
82. Janado, M.; Shimada, K.; Nishida, T. Thermodynamic characteristics of the adsorption of sulfanilamide, phenol, and n-butanol on bio-gel beads. J. Bio. Chem., 1976 79, 513-520.
83. Gagnon, P. Purification tools for monoclonal antibodies.; Validated Biosystems: San Clemente, 1996.
84. Welling, G.W.; Groen, G.; Slopsema, K.; Welling-Wester, S. Combined size-exclusion and reversed-phase high-performance liquid chromatography of a detergent extract of Sendai virus. J. Chromatogr., 1985 326, 173-178.
85. Klyushnichenko, V.E.; Wulfson, B. Recombinant human insulin-II. Size-exclusion HPLC of biotechnological precursors. Factors influencing on retention and selectivity. Pure & Appl. Chem., 1993 65, 2265-2272.
86. Ejima, D.; Yumioka, R.; Arakawa, T.; Tsumoto, K. Arginine as an effective additive in gel permeation chromatography. J. Chromatogr. A, 2005 1094, 49-55.
87. Arakawa, T.; Tsumoto, K.; Nagase, K.; Ejima, D. The effects of arginine on protein binding and elution in hydrophobic interaction and ion-exchange chromatography. Protein Expr. Purif., 2007 54, 110-116.
88. Fausnaugh, J.L.; Pfannkoch, E.; Gupta, S.; Regnier, F.E. Highperformance hydrophobic interaction chromatography of proteins. Anal. Biochem., 1984 137, 464-472.
89. Alpert, A.J. Hydrophilic-interaction chromatography for the separation of peptides, nucleic acids and other polar compounds. J. Chromatogr., 1990 499, 177-196.
90. Shukla, A.A.; Hubbard, B.; Tressel, T.; Guhan, S.; Low, D. Downstream processing of monoclonal antibodies-application of platform approaches. J. Chromatogr. B, 2007 848, 28-39.
91. Tsumoto, K.; Ejima, D.; Nagase, K.; Arakawa, T. Arginine improves protein elution in hydrophobic interaction chromatography. The cases of human interleukin-6 and activin-A. J. Chromatogr. A, 2007 1154, 81-86.
92. Arakawa, T.; Kita, Y.; Sato, H.; Ejima, D. MEP chromatography of antibody and Fc-fusion protein using aqueous arginine solution. Protein. Expr. Purif., 2009 63, 158-163.
93. Arakawa, T.; Futatsumori-Sugai, M.; Tsumoto, K.; Kita, Y.; Sato, H.; Ejima, D. MEP HyperCel chromatography II: binding, washing and elution. Protein Expr. Purif., 2010 71, 168-173.
94. Sii, D.; Sadana, A. Bioseparation using affinity techniques. J. Biotechnol., 1991 19, 83-98.
95. Stead, C.V. The use of dyes in protein purification. Bioseparation, 1991 2, 129-136.
96. Mattiasson, B.; Galaev, I. Yu.; Garg, N. Polymer-shielded dyeaffinity chromatography. J. Mol. Recognit., 1996 9, 509-514.
97. Kumar, A., Galaev, I. Yu. and Mattiasson, B. (2000) J. Chromatogr. B,. 741, 103-113.
98. Arakawa, T.; Ejima, D.; Tsumoto, K.; Ishibashi, M.; Tokunaga, M. Improved performance of column chromatography by arginine: dye-affinity chromatography. Protein Expr. Purif., 2007 52, 410-414.
99. Agraz, A.; Duarte, C.A.; Costa, L.; Pérez, L.; Páez, R.; Pujol, V.; Fontirrochi, G. Immunoaffinity purification of recombinant hepatitis B surface antigen from yeast using a monoclonal antibody. J. Chromatogr. A, 1994 672, 25-33.
100. Labrou, N.E.; Clonis, Y.D. The affinity technology in downstream processing. J. Biotechnol., 1994 36, 95-119.
101. Inagaki, M.; Watanabe, M.; Hidaka, H. N-(2-aminoethyl)-5-isoquinolinesulfonamide, a new synthesized protein kinase inhibitor, functions as a ligand in affinity chromatography. Purification of Ca2+-activated, phospholipid-dependent and other protein kinases. J. Biol. Chem., 1985 275, 2922-2925.
102. Valsasina, B.; Kalisz, H.M.; Isacchi, A. Kinase selectivity profiling by inhibitor affinity chromatography. Expert Rev. Proteomics, 2004 1, 303-315.
103. Godl, K.; Wissing, J.; Kurtenbach, A.; Habenberger, P.; Blencke, S.; Gutbrod, H.; Salassidis, K.; Stein-Gerlach, M.; Missio, A.; Cotton, M.; Daub, H. An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. Proc. Natl. Acad. Sci. USA., 2003 100, 15434-15439.
104. Bredmer, D.; Godl, K.; Zech, B.; Wissing, J.; Daub, H. Proteomewide identification of cellular targets affected by bisindoyl maleimide-type protein kinase C inhibitors. Mol. Cell Proteomocs, 2004 3, 490-500.
105. Clonis, Y.D. Affinity chromatography matures as bioinformatic and combinatorial tools develop. J. Chromatogr. A, 2006 1101, 1-24.
106. Fahrner, R.L.; Whitney, D.H.; Vanderlaan, M.; Blank, G.S. Performance comparison of protein A affinity-chromatography sorbents for purifying recombinant monoclonal antibodies. Biotechnol. Appl. Biochem., 1999 30, 121-128.
107. Hahn, R.; Schlegel, R.; Jungbauer, A. Comparison of protein A affinity sorbents. J. Chromatogr. A, 2003 790, 35-51.
108. Ejima, D.; Tsumoto, K.; Fukada, H.; Yumioka, R.; Nagase, K.; Arakawa, T.; Philo, J. Effects of acid exposure on the coformation, stability, and aggregation of monoclonal antibodies. Proteins, 2007 66, 954-962.
109. Arakawa, T.; Philo, J.S.; Tsumoto, K.; Yumioka, R.; Ejima, D. Elution of antibodies from a Protein-A column by aqueous arginine solutions. Protein Expr. Purif., 2004 36, 244-248.
110. Ejima, D.; Yumioka, R.; Tsumoto, K.; Arakawa, T. Effective elution of antibodies by arginine and arginine derivatives in affinity column chromatography. Anal. Biochem., 2005 345, 250-257.
111. Yumioka, R.; Tsumoto, K.; Arakawa, T.; Ejima, D. Screening of effective column rinse solvent for Protein-A chromatography. Protein Expr. Purif., 2010 70, 218-223.
112. Ritzén, U.; Rotticci-Mulder, J.; Ströminger, P.; Schmidt, S.R. Endotoxin reduction in monoclonal antibody preparation using arginine. J. Chromatogr. B, 2007 856, 343-347.
113. Falconer, R.J.; Chan, C.; Hughes, K.; Munro, T.P. Stabilization of a monoclonal antibody during purification and formulation by addition of basic amino acid excipients. J. Chem. Technol. Biotechnol., 2011 86, 942-948.
114. Yamasaki, H.; Tsujimoto, K.; Koyama, A.H.; Ejima, D.; Arakawa, T. Arginine facilitates inactivation of enveloped viruses. J. Pharm. Sci., 2008 97, 3063-3073.
115. Katsuyama, Y.; Yamasaki, H.; Tsujimoto, K.; Koyama, A.H.; Ejima, D.; Arakawa, T. Butyroyl-arginine as a potent virus inactivation agent. Int. J. Pharm., 2008 361, 92-98.
116. Utsunimoya, H.; Ichinose, M.; Tsujimoto, K.; Katsuyama, Y.; Yamasaki, H.; Koyama, A.H.; Ejima, D.; Arakawa, T. Cooperative thermal inactivation of herpes simplex virus and influenza virus by arginine ans NaCl. Int. J. Pharm., 2009 366, 99-102.
117. Arakawa, T.; Kita, Y.; Koyama, A.H. Synergistic virus inactivation effects of arginine. Biotechnol. J., 2009 4, 174-178.
118. Tsujimoto, K.; Uozaki, M.; Ikeda, K.; Yamazaki, H.; Utsunomiya, H.; Ichinose, M.; Koyama, A.H.; Arakawa, T. Solvent-induced virus inactivation by acidic arginine solution. Int. J. Mol. Med., 2010 25, 433-437.
119. Naito, T.; Irie, H.; Tsujimoto, K.; Ikeda, K.; Arakawa, T.; Koyama, A.H. Antiviral effect of arginine against herpes simplex virus type 1. Int. J. Mol. Med., 2009 23, 495-499.
120. Ohtake, S.; Arakawa, T.; Koyama, A.H. Arginine as a synergistic agent. Molecules, 2010 15, 1408-1424.
121. Nishide, M.; Tsujimoto, K.; Uozaki, M.; Ikeda, K.; Yamasaki, H.; Koyama, A.H.; Arakawa, T. Effects of electrolytes on virus inactivation by acidic solutions. Int. J. Mol. Med., 2011 27, 803-809.
122. Ikeda, K.; Yamasaki, H.; Minami, S.; Naito, T.; Irie, H.; Arakawa, T.; Koyama, A.H. Virucidal ability of arginine and its possible application as an antiherpetic agent. Int. J. Mol. Med., 2012, in press.
123. Hofmeister, F. Zue Lehre von der Wirkung der Saltze. Arch. Exp. Pathol. Pharmakol., 1888 24, 247-260.
124. Traube, J. The attraction pressure. J. Phys. Chem., 1910 14, 451-470.
125. Traube, J. Theory of attraction pressure. J. Phys. Chem., 1910 14, 471-475.
126. Lee, J.C.; Timasheff, S.N. The stabilization of proteins by sucrose. J. Biol. Chem., 1981 256, 7193-7201.
127. Gekko K, Timasehff SN. Mechanism of protein stabilization by glycerol: preferential hydration in glycerol-water mixtures. Biochemistry, 1981 20, 4667-4676.
128. Chen, B.L.; Arakawa, T. Stabilization of recombinant human keratinocyte growth factor by osmolytes and salts. J. Pharm. Sci., 1996 85, 419-426.
129. Gerlsma, S.Y. Reversible denaturation of ribonuclease in aqueous solution as influenced by polyhydric alcohols and some other additives. J. Biol. Chem., 1968 243, 957-961.
130. Gerlsma, S.Y. The effects of polyhydric and monohydric alcohols on the heat induced reversible denaturation of chymotrypsinogen A. Eur. J. Biochem., 1970 14, 150-153.
131. von Hippel, P.H.; Wong, K.Y. The effects of ions on the kinetics of formation and the stability of the collagen fold. Biochemistry, 1962 1, 664-674.
132. von Hippel, P.H.; Wong, K.Y. On the conformational stability of globular proteins. J. Biol. Chem., 1965 240, 3909-3923.
133. Weisenberg, R.C.; Timasheff, S.N. Aggregation of microtubule subunit protein. Effects of divalent cations, colchicine and vinblastine. Biochemistry, 1970 9, 4110-4116.
134. Frigon, R.P.; Timasheff, S.N. Magnesium-induced self-association of calf brain tubulin. I. Stoichiometry. Biochemistry, 1975 14, 4559-4566.
135. Frigon, R.P.; Lee, J.C. The stabilization of calf-brain microtubule protein by sucrose. Arch. Biochem. Biophys., 1972 153, 587-589.
136. Erickson, H.P. Microtubule surface lattice and subunit structure and observations on reassembly. J. Cell Biol., 1974 60, 153-167.
137. Erickson, H.P. Assembly of microtubules from preformed, ringshaped protofilaments and 6-S tubulin. J. Supramol. Struc., 1974 2, 393-411.
138. Shelanski, M.L.; Gaskin, F.; Cantor, C.R. Microtubule assembly in the absence of added nucleotides. Proc. Natl. Acad. Sci. USA., 1973 70, 765-768.
139. Kasai, M.; Nakano, E.; Oosawa, F. Polymerization of actin free from nucleotides and divalent cations. Biochim. Biophys. Acta, 1965 94, 494-503.
140. Sinanoglu, O.; Abdulnur, S. Hydrophobic stacking of bases and the solvent denaturation of DNA. J. Photochem. Photobiol., 1964 3, 333-342.
141. Sinanoglu, O.; Abdulnur, S. Effect of water and other solvents on the structure of biopolymers. Fed. Proc, 1965, 24, S12-23.
142. Sinanoglu, O.; Halicioglu, H. Solvent effects on Cis-Trans, azobenzene isomerization-a detailed application of a theory of solvent effects on molecular associations. Ann. N. Y. Acad. Sci., 1969 158, 308-312.
143. Melander, W.; Horvath, C. Salt effect on hydrophobic interaction in precipitation and chromatography of proteins: An interpretation of the lyotropic series. Arch. Biochem. Biophys., 1977 183, 200-215.
144. Robinson, D.R.; Jencks, W.P. The Effect of Concentrated Salt Solutions on the Activity Coefficient of Acetyltetraglycine Ethyl Ester. J. Am. Chem. Soc., 1965 87, 2470-2479.
145. Arakawa, T.; Timasheff, S.N. Preferential interactions of proteins with salts in concentrated solutions. Biochemistry, 1982 21, 6545-6552.
146. Arakawa, T.; Timasheff, S.N. Mechanism of protein salting in and salting out by divalent cation salts: balance between hydration and salt binding. Biochemistry, 1984 2, 5912-5923.
147. Arakawa, T.; Timasheff, S.N. Protein stabilization and destabilization by guanidinium salts. Biochemistry, 1984 23, 5924-5929.
148. Arakawa, T.; Bhat, R.; Timasheff, S.N. Why preferential hydration does not always stabilize the native structure of globular proteins. Biochemistry, 1990 29, 1924-1931.
149. Arakawa, T.; Bhat, R.; Timasheff, S.N. Preferential interactions determine protein solubility in three-component solutions: the MgCl2 system. Biochemistry, 1990 29, 1914-1923.
150. Breslow, R.; Guo, T. Surface tension measurements show that chaotropic salting-in denaturants are not juts water-structure breakers. Proc. Natl. Acad. Sci. USA., 1990 87, 167-169.
151. Siskova, M.; Hejtamankova, J.; Bartovska, L. Cell. Czech. Chem. Commun., 1985, 50, 1629-1635.
152. Nozaki, Y.; Tanford, C. The solubility of amino acids and related compounds in aqueous ethylene glycol solutions. J. Biol. Chem., 1965 240, 3568-3575.
153. Nozaki, Y.; Tanford, C. The Solubility of Amino Acids and Related Compounds in Aqueous Urea Solutions. J. Biol. Chem., 1963 238, 4074-4081.
154. Nozaki, Y.; Tanford, C. The solubility of amino acids, diglycine, and triglycine in aqueous guanidine hydrochloride solutions. J. Biol. Chem., 1970 245, 1648-1652.
155. Nozaki, Y.; Tanford, C. The solubility of amino acids and two glycine peptides in aqueous ethanol and dioxane solutions. Establishment of a hydrophobicity scale. J. Biol. Chem., 1971 246, 2211-2217.
156. Gekko, K.; Morikawa, T. Preferential hydration of bovine serum albumin in polyhydric alcohol-water mixtures. J. Biochem., 1981 90, 39-50.
157. Liu, Y.; Bolen, D.W. The peptide backbone plays a dominant role in protein stabilization by naturally occurring osmolytes. Biochemistry, 1995 34, 12884-12891.
158. Arakawa, T.; Timasheff, S.N. Protein precipitation and denaturation by dimethyl sulfoxide. Biophys. Chem., 2007 131, 62-70.
159. Bull, H.B.; Breese, K. Interaction of alcohols with proteins. Biopolymers, 1978 17, 2121-2131.
160. Inoue, H.; Timasheff, S.N. The interaction of beta-lactoglobulin with solvent components in mixed water-organic solvent systems. J. Am. Chem. Soc., 1968 90, 1890-1898.
161. Lee, J.C.; Gekko, K.; Timasheff, S.N. Measurements of preferential solvent interactions by densimetric techniques. Methods Enzymol., 1979 61, 26-49.
162. Lee, J.C.; Timasheff, S.N. Partial specific volumes and interactions with solvent components in guanidine hydrochloride. Biochemistry, 1974 13, 257-265.
163. Prakash, V.; Loucheux, C.; Scheufele, S.; Gorbunoff, M.J.; Timasheff, S.N. Interaction of proteins with solvent components in 8 M urea. Arch. Biochem. Biophys., 1981 210, 455-464.
164. Hong, J.; Capp, M.W.; Anderson, C.F.; Record, M.T. Preferential interactions in aqueous solution of urea and KCl. Biphys. Chem., 2003 105, 517-532.
165. Timasheff, S.N.; Xie, G. Preferential interactions of urea with lysozyme and their linkage to protein denaturation. Biophys. Chem., 2003 105, 421-448.
166. Timasheff, S.N.; Inoue, H. Preferential binding of solvent components to proteins in mixed water-organic solvent systems. Biochemistry, 1968 7, 2501-2513.
167. Inoue, H.; Timasheff, S.N. Preferential and absolute interactions of solvent components with proteins in mixed solvent systems. Biopolymers, 1972 11, 737-743.
168. Pittz, E.P.; Timasheff, S.N. Interaction of ribonuclease A with aqueous 2-methyl-2,4-pentanediol at pH 5.8. Biochemistry, 1978 17, 615-623
169. Arakawa, T.; Timasheff, S.N. Stabilization of protein structure by sugars. Biochemistry, 1982 21, 6536-6544.
170. Arakawa, T.; Timasheff, S.N. Preferential interactions of proteins with solvent components in aqueous amino acid solutions. Arch. Biochem. Biophys., 1983 224, 169-177.
171. Arakawa, T.; Timasheff, S.N. The mechanism of action of Na glutamate, lysine HCl, and piperazine-N, N'-bis(2-ethanesulfonic acid) in the stabilization of rubulin and microtuble formation. J. Biol. Chem., 1984 259, 4979-4586.
172. Arakawa, T.; Timasheff, S.N. The stabilization of proteins by osmolytes. Biophys. J., 1985 47, 411-414.
173. Arakawa, T.; Timasheff, S.N. Theory of protein solubility. Methods Enzymol., 1985 114, 49-77.
174. Arakawa, T.; Timasheff, S.N. Abnormal solubility behavior of beta-lactoglobulin: salting-in by glycine and NaCl. Biochemistry, 1987 26, 5147-5153.
175. Pappenheimer, J.R.; Lepie, M.P.; Wyman, J. The surface tension of aqueous solutions of dipolar ions. J. Am. Chem. Soc., 1963 58, 1851-1855.
176. Kita, Y.; Arakawa, T.; Lin, T.Y.; Timasheff, S.N. Contribution of the surface free energy perturbation to protein-solvent interactions. Biochemistry, 1994 33, 15178-15189.
177. Tischer, A.; Lilie, H.; Rudolph, R.; Lange, C. L-Arginine hydrochloride increases the solubility of folded and unfolded recombinant plasminogen activator rPA. Protein Sci., 2010 19, 1783-1795.
178. Ito, L.; Shiraki, K.; Matsuura, T.; Okumura, M.; Hasegawa, K.; Baba, S.; Yamaguchi, H.; Kumasaka, T. High-resolution X-ray analysis reveals binding of arginine to aromatic residues of lysozyme surface: implication of suppression of protein aggregation by arginine. Protein Eng. Des. Sel., 2011 24, 269-274.
179. Shukla, D.; Trout, B. Interaction of arginine with proteins and the mechanism by which it inhibits aggregation. J. Phys. Chem. B, 2010 114, 13426-13438.
180. Woods, A.S. The might arginine, the stable quaternary amines, the powerful aromatics, and the aggressive phosphate: their role in the noncovalent minuet. J. Proteome Res., 2004 3, 478-484.
181. Flocco, M.M.; Mowbray, S.L. Planar stacking interactions of arginine and aromatic side-chains in proteins. J. Mol. Biol., 1994 235, 709-717.
182. Gallivan, J.P.; Dougherty, D.A. Cation-pi interactions in structural biology. Proc. Natl. Acad. Sci. USA., 1999 96, 9459-9464.
183. Crowley, P.B.; Golovin, A. Cation-pi interactions in protein-protein interfaces. Proteins, 2005 59, 231-239.
184. Dougherty, D.A. Cation-pi interactions involving aromatic amino acids. J. Nutr. 2007, 137, 1504S-1508S.
185. Nakakido, M.; Tanaka, Y.; Mitsuhori, M.; Kudou, M.; Ejima, D.; Arakawa, T.; Tsumoto, K. Structure-based analysis reveals hydration changes induced by arginine hydrochloride. Biophys. Chem., 2008 137, 105-109.
186. Wyman, J. Linked functions and reciprocal effects in hemoglobin: a second look. Adv. Protein Chem., 1964 19, 223-286.
187. Casassa, E.F.; Eisenberg, H. Thermodynamic analysis of multicomponent solutions. Adv. Protein Chem., 1964 19, 287-395.
188. Cohen, G.; Eisenberg, H. Deoxyribonuclease solutions: sedimentation in a density gradient, partial specific volumes, density and refractive index increments, and preferential interactions. Biopolymers, 2968 6, 1077-1100.
189. Minton, A.P. Influence of macromolecular crowding upon the stability and state of association of proteins: prediction and observation. J. Pharm. Sci., 2005 94, 1668-1675.
190. Sasahara, K.; McPhie, P.; Minton, A.P. Effect of dextran on protein stability and conformation attributed to macromolecular crowding. J. Mol. Biol., 2003 326, 1227-1237.
191. Lee, J.C.; Lee, L.L. Preferential solvent interactions between proteins and polyethylene glycols. J. Biol. Chem., 1981 256, 625-631.
192. Arakawa, T.; Timasheff, S.N. Mechanism of poly(ethylene glycol) interaction with proteins. Biochemistry, 1985 24, 6756-6762.
193. Asakura, S.; Oosawa, F. Surface tension of high-polymer solutions. J. Chem. Phys., 1954 22, 1255.
194. Asakura, S.; Oosawa, F. Interactions between particles suspended in solutions of macromolecules. J. Polym. Sci., 1958 33, 183-192.
195. Schneider, C.P.; Trout, B. Investigation of cosolute-protein preferential interaction coefficients: new insight into the mechanism by which arginine inhibits aggregation. J. Phys. Chem. B., 2009 113, 2050-2058.
196. Gibbs, J.W. On the equilibrium of heterogeneous substances. Trans. Conn. Acad. Arts Sci., 1878 3, 343-524.
197. Das, U.; Hariprasad, G.; Ethayathulla, A.S.; Manral, P.; Das, T.K.; Pasha, S.; Mann, A.; Ganguli, M.; Verma, A.K.; Bhat, R.; Chandrayan, S.K.; Ahmed, S.; Sharma, S.; Kaur, P.; Singh, T.P.; Srinivasan, A. Inhibition of protein aggregation: supramolecular assemblies of arginine hold the key. PLos One, 2007 2, e1176.
198. Baynes, B.M.; Wang, D.I.; Trout, B.L. Role of arginine in the stabilization of proteins against aggregation. Biochemistry, 2005 44, 4919-4925.
199. White, S.H.; Wimley, W.C. Membrane protein folding and stability: physical principles. Annu. Rev. Biophys. Biomol. Struc., 1999 28, 319-365.
200. Hristova, K.; Wimley, W.C. A look at arginine in membranes. J. Membr. Biol., 2011 239, 49-56.
201. Yoo, J.; Cui, Q. Does arginine remain protonated in the lipid membrane? Insights from microscopic pKa calculations. Biophys. J., 2008 94, L61-63.
202. White, S.H.; Wimley, W.C.; Selsted, M.E. Structure, function, and membrane integration of defensins. Curr. Opin. Struc. Biol., 1995 5, 521-527.
203. Yount, N.Y.; Yeaman, M.R. Multidimensional signatures in antimicrobial peptides. Proc. Natl. Acad. Sci. USA., 2004 101, 7363-7368.
204. Futaki, S. Membrane-permeable arginine-rich peptides and the translocation mechanisms. Adv. Drug Deliv. Rev., 2005 57, 547-558.
205. Hirai, A.; Tanaka, S.; Kawasaki, H.; Nemoto, N.; Suzuki, M.; Maeda, H. Effects of arginine on aggregates of fatty-acid/potassium soap in the aqueous media. Colloid Polym. Sci., 2006 284, 520-528.